Hrt Financial LP Clovis Oncology, Inc. Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $606,175 - $2.85 Million	-962,183 Reduced 88.03%	130,830 $235,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $1.31 Million - $2.88 Million	916,306 Added 518.55%	1,093,013 $2.21 Million
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.76 $477,108 - $841,125	176,707 New	176,707 $478,000
Q2 2021 Aug 16, 2021	SELL	$5.02 - $7.05 $609,879 - $856,504	-121,490 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.81 - $10.34 $584,366 - $1.26 Million	121,490 New	121,490 $852,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.